GO
Loading...

Search results for ""David Faber""

REFINE RESULTS

ANY FORMAT

Blog Posts
News
Slideshows
Special Reports
» Video
Wires

Press Releases

SEARCH RESULTS

About 31 results. Sort By: Date | Relevance
Faber Report: Shopping for a deal?  

CNBC's David Faber reports on a potential takeover battle in the REIT space.
Source: CNBC.com
Faber Report: All markets love Actavis  

CNBC's David Faber has the update on the fixed income market and Actavis' $20 billion bond offering.
Source: CNBC.com
Nasdaq hits 5,000  

The Nasdaq Composite briefly hit 5,000 for the first time since March 2000 during the tech bubble, with CNBC's Bertha Coombs.
Source: CNBC.com
Faber Report: Buffett on activisim  

CNBC's David Faber shares his thoughts on Warren Buffett's comments about activist pay.
Source: CNBC.com
Lumber Liquidators tanks after '60 Minutes' report  

Shares of Lumber Liquidators are taking a deep dive after a '60 Minutes' report. CNBC's Jim Cramer and David Faber react to the news.
Source: CNBC.com
Buffett's advice for the next 50 years  

Hedge fund manager David Tepper wants to know what Warren Buffett thinks of compensation transparency and how capital allocation relates to the balance sheet. Also, Harry Wilson weighs in on General Motors, and Buffett shares a long term investment tip.
Source: CNBC.com
Rometty: IBM a high value innovation company  

IBM chairman and CEO Ginni Rometty reminded investors IBM is a high value innovation company and one that runs the critical systems of the world. CNBC's David Faber discusses how IBM should be measured on its growth initiative.
Source: CNBC.com
Trader: Buy HP dip  

Hewlett-Packard reported light guidance, citing an impact from the strong dollar. CNBC's David Faber is listening to the earnings call.
Source: CNBC.com
HP beats by a cent  

Hewlett-Packard is reporting EPS of $0.92 adjusted on revenue of $26.8 billion, with CNBC's David Faber. The company's year guidance is being reduced.
Source: CNBC.com
Cramer: Valeant still worth buying  

Rallying 15 percent into today's trade, Mad Money's Cramer dissects the performance of Valeant Pharmaceuticals.
Source: CNBC.com